Boston, United States
Invetx - a Dechra Division is a company that aims to revolutionize the animal health sector through the application of biopharma technologies, founded in 2018 and headquartered in the United States. With the slogan, "Bringing the best of biopharma to animal health," Invetx positions itself at the forefront of developing protein-based therapeutics for animals.
The company prides itself on building a biotechnology innovation platform, joining forces with reputable biotechnology firms, notable investors, and a network of industry experts from both the animal and human health sectors. The goal is to create a robust portfolio of therapies and technologies aimed at enhancing the health outcomes for pets and livestock globally.
Invetx recently secured a $60.50M Series B investment on May 10, 2022, backed by prominent investors including Novo Holdings, Casdin Capital, Eight Roads Ventures, F-Prime Capital, GV, Anterra Capital, and Tekla Capital Management. This financial backing underscores investor confidence in the company’s strategic approach and its potential to lead in animal health biotechnology.
